Biogen By Buying Nightstar Targets Ophthalmology As Emerging Growth Area

 
• By Sten Stovall

Biogen is paying around $800m cash to buy UK-based Nightstar Therapeutics, which focuses on gene therapy for retinal diseases.

Oculus
Nightstar develops gene therapies delivered by AAV for rare eye diseases • Source: Shutterstock

More from Deals

More from Business